Clinical Trials

    Showing 1 - 4 of 4 Gastrointestinal Cancers

    A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer (LUCERNA)

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ can... Read more >

    A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

    Status: Open Not Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evalu... Read more >

    Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study

    Status: Enrolling

    Investigator: Maen Abdelrahim

    Study Coordinator: Elsie Rizk

    Phone: 713.441.2557

    Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are transplant-eligible will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolizatio... Read more >

    Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)

    Status: Enrolling

    Investigator: Kevin Tran

    Study Coordinator: Safiya Joseph

    Phone: 203.308.8567

    This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care options inc... Read more >